Endocrinology Education and CME

  • Top Picks
    • In My Setting: Diabetes Care
    • Novel Therapies for LDL-C Lowering in the Fight Against Residual ASCVD Risk
    • The Emerging Biosimilar Therapeutic Landscape: Scientific Foundations and Clinical Implications
    • Navigating a New Era of Personalized Type 2 Diabetes Care: Taking the Road Less Traveled

Select a Topic

  • FILTER BY:
j319
CME

Practical Lipidology®: Volume 3, Number 1

This activity is supported by an educational grant from Amgen

Expiration Date: 7/1/2017
Credit Type(s): CME | Credit: 1.25

The reduction of low-density lipoprotein-cholesterol (LDL-C) is recognized as the primary strategy for decreasing cardiovascular risk. Despite highly effective statin…

go to activity»
Managing Obesity in 2015: Setting the Framework and Assessing All of the Options
CME

Managing Obesity in 2015: Setting the Framework and Assessing All of the Options

This activity is supported by an educational grant from Novo Nordisk.

Expiration Date: 9/3/2016
Credit Type(s): CME | Credit: 1.75

This CME activity is based on the slides and lectures presented by the faculty at the symposium, Managing Obesity in 2015: Setting the Framework and Assessing All of the…

go to activity»
Diabetic Retinopathy: The Importance of Early Screening, Referral, and Management
CME

Diabetic Retinopathy: The Importance of Early Screening, Referral, and Management

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Expiration Date: 11/15/2016
Credit Type(s): CME | Credit: 1.5

Diabetic eye disease is one of the most common causes of vision loss in the United States. As the rates of diabetes increase, the number of affected patients will rise…

go to activity»
Avoiding “Loss of Chance”…
CME

Avoiding “Loss of Chance”… Improving the Screening, Treatment, and Referral of Patients with Diabetic Retinopathy

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 9/1/2016
Credit Type(s): CME | Credit: 1.25

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United States, in part because many patients are not…

go to activity»
In My Setting Lipids

Catch up with three physicians as they provide insightful information on the topic of lipids….

go to activity»
Advances in LDL Lowering: A Focus on PCSK9 Inhibitors’ Journey from Genetics to Clinical Practice
CMECE

Advances in LDL Lowering: A Focus on PCSK9 Inhibitors’ Journey from Genetics to Clinical Practice

This activity is supported by an educational grant from Amgen, Inc.

December 21, 2015

This Clinical Advances webcast discusses the relationship between atherosclerosis progression and LDL-C levels and provides expert interpretation of clinical guidelines…

go to activity»
In My Setting: Diabetes Care

Read what three clinicians have to say about the current state of diabetes treatment options….

go to activity»
J901 COVER
CMECNECPE

The Emerging Biosimilar Therapeutic Landscape: Scientific Foundations and Clinical Implications

This activity is supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Expiration Date: 12/10/2016
Credit Type(s): CME / CNE / CPE | Credit: 1.25

Recent processes have been established to facilitate the production, validation, and utilization of biosimilars. Biosimilars are therapeutic products similar in quality…

go to activity»
Obesity Consults- Obesity Forums 2015 Highlights
CME

Obesity Consults® ObesityForum® 2015 Highlights

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Novo Nordisk, Inc.

Expiration Date: 10/1/2016
Credit Type(s): CME | Credit: 1.25

Obesity has increased dramatically in the past 20 years and is considered a health care epidemic in the United States. According to the US Centers for Disease Control…

go to activity»
Novel Therapies for LDL-C Lowering in the Fight Against Residual ASCVD Risk
CMECE

Novel Therapies for LDL-C Lowering in the Fight Against Residual ASCVD Risk

This activity is supported by an educational grant from Genzyme, a Sanofi company, sanofi-aventis U.S., and Regeneron Pharmaceuticals.

May 20, 2016

This digital monograph, featuring video snippets and key slides from the 2015 CMHC Annual meeting examines current lipid guidelines, the unmet need and residual risk of…

go to activity»
New Treatment Paradigms for Diabetic Retinopathy: Current Status and Applications for Practice
CME

New Treatment Paradigms for Diabetic Retinopathy: Current Status and Applications for Practice

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 3/10/2017
Credit Type(s): CME | Credit: 1

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United States, in part because many patients are not…

go to activity»
A Closer Look at CV Outcomes for Type 2 Diabetes Therapies: Implications for Patient Care
CMECE

A Closer Look at CV Outcomes for Type 2 Diabetes Therapies: Implications for Patient Care

This activity is supported by an educational grant from Merck & Co., Inc.

December 21, 2015

Patients with type 2 diabetes mellitus are at risk for cardiovascular disease and reducing this risk is a desirable outcome of therapy. Conflicting research on the CV…

go to activity»
j319
CME

Practical Lipidology®: Volume 3, Number 1

This activity is supported by an educational grant from Amgen

Expiration Date: 7/1/2017
Credit Type(s): CME | Credit: 1.25

The reduction of low-density lipoprotein-cholesterol (LDL-C) is recognized as the primary strategy for decreasing cardiovascular risk. Despite highly effective statin…

go to activity»
In My Setting: Diabetes Care

Read what three clinicians have to say about the current state of diabetes treatment options….

go to activity»
Managing Obesity in 2015: Setting the Framework and Assessing All of the Options
CME

Managing Obesity in 2015: Setting the Framework and Assessing All of the Options

This activity is supported by an educational grant from Novo Nordisk.

Expiration Date: 9/3/2016
Credit Type(s): CME | Credit: 1.75

This CME activity is based on the slides and lectures presented by the faculty at the symposium, Managing Obesity in 2015: Setting the Framework and Assessing All of the…

go to activity»
J901 COVER
CMECNECPE

The Emerging Biosimilar Therapeutic Landscape: Scientific Foundations and Clinical Implications

This activity is supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Expiration Date: 12/10/2016
Credit Type(s): CME / CNE / CPE | Credit: 1.25

Recent processes have been established to facilitate the production, validation, and utilization of biosimilars. Biosimilars are therapeutic products similar in quality…

go to activity»
Diabetic Retinopathy: The Importance of Early Screening, Referral, and Management
CME

Diabetic Retinopathy: The Importance of Early Screening, Referral, and Management

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Expiration Date: 11/15/2016
Credit Type(s): CME | Credit: 1.5

Diabetic eye disease is one of the most common causes of vision loss in the United States. As the rates of diabetes increase, the number of affected patients will rise…

go to activity»
Obesity Consults- Obesity Forums 2015 Highlights
CME

Obesity Consults® ObesityForum® 2015 Highlights

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Novo Nordisk, Inc.

Expiration Date: 10/1/2016
Credit Type(s): CME | Credit: 1.25

Obesity has increased dramatically in the past 20 years and is considered a health care epidemic in the United States. According to the US Centers for Disease Control…

go to activity»
Avoiding “Loss of Chance”…
CME

Avoiding “Loss of Chance”… Improving the Screening, Treatment, and Referral of Patients with Diabetic Retinopathy

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 9/1/2016
Credit Type(s): CME | Credit: 1.25

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United States, in part because many patients are not…

go to activity»
Novel Therapies for LDL-C Lowering in the Fight Against Residual ASCVD Risk
CMECE

Novel Therapies for LDL-C Lowering in the Fight Against Residual ASCVD Risk

This activity is supported by an educational grant from Genzyme, a Sanofi company, sanofi-aventis U.S., and Regeneron Pharmaceuticals.

May 20, 2016

This digital monograph, featuring video snippets and key slides from the 2015 CMHC Annual meeting examines current lipid guidelines, the unmet need and residual risk of…

go to activity»
In My Setting Lipids

Catch up with three physicians as they provide insightful information on the topic of lipids….

go to activity»
New Treatment Paradigms for Diabetic Retinopathy: Current Status and Applications for Practice
CME

New Treatment Paradigms for Diabetic Retinopathy: Current Status and Applications for Practice

This activity is supported by an educational grant from Genentech, Inc.

Expiration Date: 3/10/2017
Credit Type(s): CME | Credit: 1

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United States, in part because many patients are not…

go to activity»
Advances in LDL Lowering: A Focus on PCSK9 Inhibitors’ Journey from Genetics to Clinical Practice
CMECE

Advances in LDL Lowering: A Focus on PCSK9 Inhibitors’ Journey from Genetics to Clinical Practice

This activity is supported by an educational grant from Amgen, Inc.

December 21, 2015

This Clinical Advances webcast discusses the relationship between atherosclerosis progression and LDL-C levels and provides expert interpretation of clinical guidelines…

go to activity»
A Closer Look at CV Outcomes for Type 2 Diabetes Therapies: Implications for Patient Care
CMECE

A Closer Look at CV Outcomes for Type 2 Diabetes Therapies: Implications for Patient Care

This activity is supported by an educational grant from Merck & Co., Inc.

December 21, 2015

Patients with type 2 diabetes mellitus are at risk for cardiovascular disease and reducing this risk is a desirable outcome of therapy. Conflicting research on the CV…

go to activity»
The Role of Combination Therapies in Early, Intensive Treatment of Type 2 Diabetes
CMECE

The Role of Combination Therapies in Early, Intensive Treatment of Type 2 Diabetes

This activity is supported by an educational grant from AstraZeneca.

December 21, 2015

Despite the availability of numerous treatment options for type 2 diabetes mellitus, the number of patients achieving glycemic goals is unacceptably low. Some existing…

go to activity»
J876
CMEVIDEO

Secondary Prevention of Atherothrombotic Events: Current Insights on Advancing Science

This activity is supported by an educational grant from Merck & Co.

Expiration Date: 12/22/2016
Credit Type(s): CME | Credit: 1.25

Prevention of cardiovascular disease (CVD) is critical in light of its associated mortality, morbidity, and economic burden. Preexisting conditions – including diabetes…

go to activity»
J871 Cover Image
CMEVIDEO

Navigating a New Era of Personalized Type 2 Diabetes Care: Taking the Road Less Traveled

This activity is supported by an independent educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Expiration Date: 11/19/2016
Credit Type(s): CME | Credit: 2

In the United States, over 29 million people have diabetes, of which approximately 95% of cases are type 2 diabetes mellitus (T2DM). While developments in the…

go to activity»
morganatic-roan